Pharmabiz :: Affymax settles peginesatide patent litigation with Janssen Biotech

Affymax, Inc., a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions, has reached a global settlement agreement with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson, and certain of its affiliated companies to end the arbitration and litigation related to certain intellectual property emerging from a 1992-1995 research collaboration.